AstraZeneca and Bristol Myers Squibb denied merger talks, dispelling rumors of a $400 billion deal that previously caused significant share price movements.
An editorial advises AstraZeneca against a proposed $400bn merger with Bristol Myers Squibb, recommending it stick to its organic growth strategy rather than high-risk financial engineering. Concerns
Gulf chemical manufacturers continue operations despite regional conflicts, while Bristol Myers Squibb and AstraZeneca are reportedly exploring a merger.
Japan and the US executed a historic $60 billion joint yen intervention to stabilize the currency. Concurrently, oil prices fell 5% on geopolitical developments, while AstraZeneca shares dipped amid p
US stocks hit record highs as Iran talks reduced oil prices by 5%, while Bristol Myers Squibb and AstraZeneca began merger talks potentially forming a $400 billion drugmaker.
Financial Times reports AstraZeneca and Bristol Myers Squibb are exploring a potential $400 billion merger to create a top global pharmaceutical group. Recent strong sales in oncology and rare disease
ChemBrief